USA SaMD & The RWE Paradox: A Pure Global Briefing

Failed to add items

Sorry, we are unable to add the item because your shopping basket is already at capacity.

Add to cart failed.

Please try again later

Add to wishlist failed.

Please try again later

Remove from wishlist failed.

Please try again later

Follow podcast failed

Unfollow podcast failed

USA SaMD & The RWE Paradox: A Pure Global Briefing

Listen for free

View show details

About this listen

This week, we dissect the FDA's sudden and impactful new guidance on Real-World Evidence (RWE) that just sent ripples through the US digital health sector. This isn't just another update; it's a fundamental shift in how data from wearables and EHRs will be scrutinized, potentially derailing existing regulatory strategies for countless SaMD and AI-driven medical devices. We explore the new, stricter demands for data integrity and what it means for companies that have banked their futures on the promise of RWE. We break down the strategic pivots innovators must now consider to stay compliant and competitive, transforming a potential regulatory crisis into a strategic advantage. **Case Study:** A leading digital health firm has spent two years and millions of dollars building a product roadmap based on leveraging real-world data for rapid market expansion. Last week, the new FDA guidance rendered their entire evidence portfolio questionable, putting their next funding round and product launches in jeopardy. Their data asset has suddenly become a massive liability. **What You'll Learn:** 1. What are the critical new data integrity rules in the FDA's RWE guidance? 2. Is your current Real-World Evidence strategy now obsolete? 3. Why did a past failure of a cardiac monitoring app trigger this FDA crackdown? 4. What specific validation steps are now required for data from wearables? 5. How does this shift impact the valuation of digital health startups? 6. What is the new cost of bringing an RWE-supported device to market? 7. How can you turn this regulatory hurdle into a competitive advantage? 8. Will the EU and other markets follow the FDA's lead? For a deeper dive into crafting a resilient global regulatory strategy, contact us at info@pureglobal.com, visit https://pureglobal.com/, or explore our FREE AI tools and medical device database at https://pureglobal.ai/.

No reviews yet